Tirzepatide set a new benchmark for metabolic research when its Phase 3 data showed weight loss significantly exceeding what had been achieved with GLP-1 agonists alone. Now Retatrutide — the triple agonist adding glucagon receptor activation to the GLP-1/GIP combination — is being positioned as the next step forward. Here’s what the data actually shows.

The Mechanistic Difference

Both tirzepatide and retatrutide activate GLP-1 and GIP receptors. The key difference is the addition of glucagon receptor agonism in retatrutide.

Glucagon has traditionally been associated with raising blood glucose — the opposite of what you want in a metabolic therapy. But at controlled doses, glucagon receptor activation drives energy expenditure through lipolysis and thermogenesis in ways that GLP-1 and GIP cannot replicate. The net effect is increased fat burning and energy output alongside the appetite suppression and insulin sensitisation delivered by the GLP-1/GIP components.

The result is a compound that addresses energy intake, glucose regulation, and energy expenditure through three distinct pathways — versus tirzepatide’s two.

What the Phase 2 Data Shows

In Phase 2 trials, retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity. For context, tirzepatide’s landmark SURMOUNT-1 trial showed approximately 20-21% weight loss at comparable timepoints in similar populations.

The difference — roughly 3-4 percentage points — is clinically meaningful at scale. In a population with severe obesity, that delta represents a significant additional reduction in metabolic burden, cardiovascular risk, and co-morbidity.

In the Type 2 diabetes cohort, retatrutide delivered 16.9% weight loss after 36 weeks, with HbA1c improving by 2.2% and 82% of participants reaching HbA1c at or below 6.5%.

Phase 3: TRIUMPH

Retatrutide is now in a large Phase 3 programme — the TRIUMPH trials — covering obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and liver disease. The first positive Phase 3 result (TRIUMPH-4, knee osteoarthritis) was announced in December 2025. Seven additional trials are expected to report throughout 2026.

Tirzepatide, by contrast, already holds regulatory approval in major markets for both type 2 diabetes and obesity. Retatrutide remains investigational.

What This Means for Researchers

For researchers in Australia investigating metabolic mechanisms, the retatrutide vs tirzepatide comparison is one of the most scientifically productive questions in the field right now. The incremental contribution of glucagon receptor co-activation — how much of retatrutide’s superior efficacy is attributable to the glucagon component, and through which specific pathways — is an active area of investigation.

Australian Peptides supplies Retatrutide in 10mg and 20mg formats for research purposes.